Basel, December 2025 — RC2NB is pleased to share an important milestone in the Clinnova-MS Basel study: the first participants have successfully completed their 1-year follow-up visit at University Hospital Basel.
This milestone represents not only scientific progress, but also sustained patient engagement and meaningful integration of digital tools into everyday life. Early participant experiences highlight strong engagement with the dreaMS App, which enables continuous, unobtrusive monitoring through gamified mobility and cognitive tasks.
Such engagement is made possible through the dedication of participants and the close support provided by the local study team. Their work reflects the Clinnova vision of patient-centred research that is both scientifically robust and seamlessly embedded into daily routines.
“Reaching our first year follow-up is an important milestone for Clinnova-MS and for the broader vision of Clinnova. It demonstrates that digital, federated, and patient-centred research is not only feasible, but already generating the real-world insights we need to better understand multiple sclerosis in all its complexity.”
— Cristina Granziera, MD, PhD, Principal Investigator, Clinnova-MS Basel
With ongoing recruitment and follow-up activities across participating European centres, Clinnova continues to build a comprehensive real-world dataset while ensuring data privacy through a federated research approach. This first 1-year follow-up milestone highlights the growing momentum of the Clinnova initiative and the essential contribution of patients and study teams across the consortium.
